November 2014

Spectranetics Overcomes Intellectual Property Challenges to Acquire Stellarex Platform

United States - Colorado

Our firm represented the Spectranetics Corporation in its purchase of the Stellarex drug-coated balloon platform from Covidien LP. The transaction involved unique intellectual property challenges, in that Covidien had divested the Stellarex platform during its acquisition by Medtronic. Our IP team was able to respond rapidly by performing intellectual property due diligence to ensure Spectranetics was able to acquire the desired technology. 

Related Legal Services

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.